ORGANIC
LETTERS
XXXX
Vol. XX, No. XX
000–000
Enantioselective Total Synthesis
of (þ)-Colletoic Acid via Catalytic Asymmetric
Intramolecular Cyclopropanation of an
r‑Diazo-β-keto Diphenylphosphine Oxide
Takashi Sawada and Masahisa Nakada*
Department of Chemistry and Biochemistry, School of Advanced Science and
Engineering, Waseda University, 3-4-1 Ohkubo, Shinjuku-ku, Tokyo 169-8555, Japan
Received December 18, 2012
ABSTRACT
The enantioselective total synthesis of (þ)-colletoic acid, a potent naturally occurring 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
inhibitor, is described. This total synthesis features a highly enantioselective catalytic asymmetric intramolecular cyclopropanation of an R-diazo-β-keto
diphenylphosphine oxide and five highly stereoselective reactions (cyclopropane opening, DielsꢀAlder reaction, iodolactonization, alkene formation,
and reduction of R,β-unsaturated carboxylic acid).
(þ)-Colletoic acid (Figure 1) was isolated from a fungus
identified as Colletotrichum gloeosporioides SANK 21404
by a research group at Daiichi Sankyo Co., Ltd.1 The relative
stereochemistry of (þ)-colletoic acid was confirmed by X-ray
crystallographic analysis, and its absolute structure was
elucidated by a modified Mosher’s method.1 (þ)-Colletoic
acid is a potent naturally occurring inhibitor of human 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) with an
IC50 of 13 nM and a Ki value of 3.9 nM but exhibits almost no
effect on 11β-HSD2 (IC50 = >10000 nM).
Although 11β-HSD1 is an NADP(H)-dependent oxi-
doreductase, it primarily acts as a reductase in intact cells,
converting inactive cortisone to cortisol, a potent bioactive
hormone in humans. Cortisol elevates blood glucose levels
by increasing glucose production in the liver as well as by
inhibiting uptake and disposal of glucose in muscle and
adipose tissues.2
Consequently, it has been suggested that metabolic
syndrome may be attributed to increased levels of cortisol,
which may be derived from elevated 11β-HSD1 activity,
and that inhibition of 11β-HSD1 may reduce cortisol. Thus,
11β-HSD1 has been a promising target for the treatment of
diseases associated with metabolic syndrome.3
(þ)-Colletoic acid is a member of the acorane-type
sesquiterpenes,4 a class of molecules featuring a spiro-
[4.5]decane core, which consists of a six-membered ring
containing a methallyl alcohol and a five-membered ring
bearing cis-oriented isopropyl and carboxyl groups. The
core of (þ)-colletoic acid possesses four stereogenic centers,
three of which are successive and incorporate the all-carbon
quaternary stereogenic spiro center.
(3) (a) Wang, M. Curr. Opin. Invest. Drugs 2006, 7, 319. (b) Barf, T.;
Williams, M. Drugs Future 2006, 31, 231. (c) Fotsch, C.; Askew, B. C.;
Chen, J. J. Expert Opin. Ther. Patents 2005, 15, 289. (d) Chrousos, G. P.
Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6329. (e) Walker, B. R.; Seckl,
J. R. Expert Opin. Ther. Targets 2003, 7, 771. (f) Masuzaki, H.; Flier,
J. S. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2003, 3, 255.
(g) Stewart, P. M. Eur. J. Endocrinol. 2003, 149, 163.
(4) For recently reported acorane-type sesquiterpenes, see: (a) Sun,
L.; Li, D.-L.; Tao, M.-H.; Dan, F.-J.; Zhang, W.-M. Helv. Chim. Acta
2012, 95, 157. (b) Song, T.-F.; Zhang, W.-D.; Xia, X.-H.; Shen, Y.-H.;
Liu, C.-M.; Lin, S.; Jin, H.-z.; Li, H.-L. Arch. Pharm. Res. 2009, 32, 1233.
(c) Nagashima, F.; Suzuki, M.; Takaoka, S.; Asakawa, Y. J. Nat. Prod.
2001, 64, 1309.
(1) Aoyagi, A.; Ito-Kobayashi, M.; Ono, Y.; Furukawa, Y.; Takahashi,
M.; Muramatsu, Y.; Umetani, M.; Takatsu, T. J. Antibiot. 2008,
61, 136.
(2) (a) Draper, N.; Stewart, P. M. J. Endocrinol. 2005, 186, 251.
(b) Thieringer, R.; Hermanowski-Vosatka, A. Expert Rev. Cardiovasc.
2005, 3, 911. (c) Morton, N. M.; Paterson, J. M.; Masuzaki, H.; Holmes,
M. C.; Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.;
Seckl, J. R. Diabetes 2004, 53, 931.
r
10.1021/ol303459x
XXXX American Chemical Society